Norepinephrine biosynthesis pathway (NE biosynthesis)

The norepinephrine biosynthesis pathway is a multi-step enzymatic process that converts the amino acid L-tyrosine into norepinephrine, a key neurotransmitter and hormone (StatPearls, NBK507716). The process begins with the hydroxylation of tyrosine to L-DOPA by tyrosine hydroxylase, which serves as the rate-limiting step in catecholamine synthesis (UniProt, P07101). L-DOPA is then decarboxylated to dopamine by aromatic L-amino acid decarboxylase, and finally, dopamine is converted to norepinephrine by dopamine beta-hydroxylase (NIH, NBK1474). This pathway is vital for maintaining cardiovascular homeostasis and modulating arousal, attention, and stress responses in the central and peripheral nervous systems. Clinical applications involve targeting these enzymes to treat conditions like pheochromocytoma, where metyrosine is used to inhibit tyrosine hydroxylase and reduce catecholamine excess (PubChem, CID 4137). Conversely, precursors like levodopa are administered to bypass early pathway steps in neurodegenerative diseases like Parkinson's (StatPearls, NBK507716). Dysregulation of this pathway is also linked to psychiatric disorders such as ADHD and depression, making it a focal point for psychopharmacological research.

Other names

Noradrenaline biosynthesis pathwayCatecholamine biosynthetic pathwayNorepinephrine synthesisCatecholamine synthesis pathway

Inhibition of rate-limiting enzymes (e.g., tyrosine hydroxylase) or downstream conversion enzymes (e.g., dopamine beta-hydroxylase) to modulate the systemic and synaptic availability of norepinephrine.